Lincoln Pharmaceuticals (531633) Q1 25/26 earnings summary

Executive summary

• Standalone net profit for Q1 FY26 rose 16.93% year-over-year to Rs. 27.70 crore, with total income up 7.39% to Rs. 169.34 crore and EBITDA up 17.92% to Rs. 39.08 crore.

• The company targets Rs. 1,000 crore revenue in three years, aiming for 15-18% annual growth, driven by expansion in cardiac, diabetic, dermatology, and ENT segments.

• FIIs increased their holding to 5.13% as of June 2025 from 3.95% a year earlier.

• Bulk Drug Manufacturing Plant commenced operations, with product approval for 10 products and a planned Rs. 4 crore investment from internal accruals.

• Board approved re-appointment of key directors and appointment of a new Secretarial Auditor for a five-year term.

Financial highlights

• Standalone total income for Q1 FY26: Rs. 169.34 crore (up 7.39% YoY); EBITDA: Rs. 39.08 crore (up 17.92% YoY); Net profit: Rs. 27.70 crore (up 16.93% YoY); EPS: Rs. 13.82.

• Consolidated total income for Q1 FY26: Rs. 169.34 crore; Net profit: Rs. 27.68 crore; EPS: Rs. 13.82.

• Gross margin and other key ratios not explicitly stated, but strong return ratios and no term debt highlighted.

Outlook and guidance

• Aims for 15-18% annual growth rate and Rs. 1,000 crore revenue within three years.

• Plans to expand exports from 60+ to 90 countries in 2-3 years, with recent entry into Canada and regulatory approvals from TGA-Australia and EU GMP.

• Focus on expanding product registrations and strengthening presence in regulated and semi-regulated markets.